Viewing Study NCT05263505


Ignite Creation Date: 2025-12-25 @ 3:31 AM
Ignite Modification Date: 2025-12-26 @ 2:13 AM
Study NCT ID: NCT05263505
Status: TERMINATED
Last Update Posted: 2023-11-07
First Post: 2022-02-16
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
Sponsor: Washington University School of Medicine
Organization:

Study Overview

Official Title: Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
Status: TERMINATED
Status Verified Date: 2023-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Sponsor
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Ocular mucous membrane pemphigoid (MMP) is an autoimmune, scarring conjunctivitis that can lead to vision loss and permanent disability. It is a rare disorder with an estimated incidence of 1 in 60,000. There are currently no FDA-approved medications for the treatment of mucous membrane pemphigoid, highlighting a clear unmet need.

At present, moderate to severe disease requires off-label use of potent immunosuppressive agents, such as oral anti-proliferatives (methotrexate, azathioprine, and mycophenolate), rituximab (RTX) or cyclophosphamide (CyC). Recently, Janus kinase (JAK) inhibition with baricitinib or tofacitinib been reported to be successful in one case of ocular MMP.

This is a randomized, single-masked, two-arm study of baricitinib vs anti-proliferatives for ocular MMP.
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: